A Phase 2 interventional study of Placebos and Leronlimab (700mg) in Coronavirus Disease 2019, sponsored by CytoDyn, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-11.
Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 777th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 349 in phase 2, and was the 864th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 504 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
CytoDyn, Inc. has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injections in subjects experiencing prolonged symptoms (> 12 weeks) of COVID-19.
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with prolonged symptoms caused by Coronavirus Disease 2019 (COVID-19). Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.
The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period. Total study duration is 91 days. The study will be conducted at up to 5 centers in the United States and planned number of subjects are 50 subjects.
Visit schedule:
Visit 1 - Screening assessment Visit 2 - baseline, first dose Visit 3 - no dose, baseline+3 days Visit 4 - second dose, baseline + 7 days Visit 5 - no dose, safety assessment/con med, baseline +10 days Visit 6 - third dose, baselines + 14 days Visit 7 - no dose, safety assessments, baseline + 17 days Visit 8 - fourth dose, baseline +21 days Visit 9 - no dose, safety assessment, baseline + 24 days Visit 10 - fifth dose, baseline + 28 days Visit 11 - no dose, safety assessment, baseline + 31 days Visit 12 - sixth dose, baseline + 35 days Visit 13 - no dose, safety assessment, baseline + 38 days Visit 14 - seventh dose, baseline + 42 days Visit 15 - no dose, safety assessment, baseline + 45 days Visit 16 - eighth and final dose, baseline + 49 days Visit 17 - End of treatment, baseline + 56 days
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical Symptom Score of ≥6 AND at least two symptoms of moderate or higher severity as listed below at the time of Screening and currently experiencing two or more of the following symptoms consistent with COVID-19 infection for a prolonged period of time (>12 weeks).
Clinical symptoms include the following:
Note: Clinical Symptom Score is obtained from the patient diary (refer to Appendix 1 for scoring instructions).
(ECG) with no findings as assessed by the Investigator.
Note: Below are the examples of clinically significant and non-clinically significant ECG abnormalities:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Syringes containing normal saline for injection were prepared by an unblinded pharmacist at the clinical sites for use as the placebo.
Drug: Placebos
Each vial of active contains 350mg of leronlimab at a concentration of 175mg/ml (nominal 2mL fill volume) in formulation buffer containing histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections
Drug: Leronlimab (700mg)
Placebos
Also known as: placebo
Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Also known as: Pro140
Changes From Baseline in Daily COVID-19-related Symptom Severity Score Through Day 56.
Changes in common COVID-19-related symptoms were evaluated daily by the patient using a patient diary between start and end of treatment. The diary is shown in Appendix 17.1 in the protocol and covers patient-reported changes for symptoms (ranked as none = 0, mild = 1, moderate = 2 or severe = 3) of cough, sore throat, stuffy or runny nose, difficulty breathing, feeling tightness in chest, feeling fast heartbeat, fatigue, exertional malaise, muscle aches and cramps, muscle weakness, joint pain and swelling, shivering and chills, feeling hot or feverish, difficulty concentrating, insomnia, headache, dizziness, anxiety, tingling or numbness, nausea, vomiting, diarrhea, sense of smell, sense of taste. Maximum score could be 70 (22 parameters with scores up to 3, two parameters with scores up to 2), lowest score could be 0. A negative value shows improvement in symptoms. The lower the value, the greater the improvement (i.e., a score of -16 is greater improvement than a score of -8).
Time frame: Changes in COVID-19 related symptoms from baseline (start of treatment) and day 56 (end of treatment)
Duration of COVID-19 Associated Symptoms From Start of Study Treatment (Day 0) Based on Self-assessment Using Daily Symptom Diary.
Number of days when any symptoms scored as moderate or severe at baseline (Day 0) are still scored as moderate or severe through day 56 (end of treatment) or symptoms scored as mild or absent at baseline are scored as mild or worse at day 56 (end of treatment).
Time frame: Duration of symptoms from baseline (day 0, start of treatment) and day 56 (end of treatment)
Number of Days Free of Symptoms Associated With COVID-19 That Were Present at the Start of Study Treatment (Day 0) Based on Self-assessment Using Daily Symptom Diary.
Symptom-free days are defined as number of days when any symptoms scored as mild, moderate or severe at baseline are scored as absent (or none) through Day 56 (end of treatment) using a self-assessment diary.
Time frame: Between start of treatment (day0) and day 56 (end of treatment)
Progression (or Worsening) of COVID-19-associated Symptoms Through Day 56 Compared to Baseline.
Progression or worsening of symptoms is defined as number of days when any symptoms scored as 2 at baseline scored as 3 through day 56 or 1 at baseline are scored as 2 or 3 through day 56 or scored 0 at study entry scored as 1, 2 or 3 through day 56. No change in symptoms would give a score of 0, symptom progression would give a positive number, symptom improvement would a negative number. Minimum baseline symptom score for eligibility for the study was 6. Maximum symptom score is 70, therefore if all symptoms progressed to the severest level the change in score would be +64. If all patients had a severe score for all symptoms at baseline and all improved to no symptoms at day 56, the maximum improvement in score would be -70.
Time frame: Between start of treatment (day0) and day 56 (end of treatment)
Change From Baseline in PROMIS® Fatigue Score at Days 7,14, 21, 28, 35, 42 and End of Treatment (Day 56).
Change from baseline in physical and psychological fatigue measured using the PROMIS® scale. A decrease in the score compared to baseline shows an improvement in the symptom. PROMIS definition - Patient-Reported Outcomes Measurement Information System. The Fatigue Short Form (4a) was used (Section 17.3 Appendix 3 of protocol). Raw fatigue scores range from 4 to 20 and are converted to a T-score metric where the response from the general population is set at 50 with standard deviations at 10; a score of greater than 60 would be one std dev greater than the general population, meaning more fatigue. A link to the fatigue score maps is provided in the hyperlinks section. The minimum fatigue T-score is 33.7 (with a std error of 4.9) and a maximum score of 75.8 (with a std error of 3.9). The higher the score, the more fatigue. A decrease in the fatigue score from baseline to day 28 and day 56 would indicate decrease in fatigue.
Time frame: Between Baseline (day 0), Visit 4 (day 7), Visit 6 (day 14), Visit 8 (day 21) Visit 10 (day 28), Visit 12 (day 35), Visit 14 (day 42), Visit 16 (Day 56) and Visit 17 (day 56, end of treatment).
Change From Baseline in PROMIS® Cognitive Function Score at Days 7, 14, 21, 28, 35, 42, 49 and End of Treatment (d56)
Change in cognitive function score between baseline, day 28 and day 56 were measured using the PROMIS Cognitive Function Assessment Short Form 4a. Higher scores on the PROMIS Cognitive Function Assessment indicate better perceived cognitive functioning. Answers to 4 questions with scores ranging from 1 (very often - several times a day) to 5 (never) provide raw scores that are then normalized T scores. A T score of 50 is the mean of the general population, with std devs of 10, therefore a score of 40 is one std dev lower than that of the general population. The lowest raw score (4) converts to a T score of 24.99 while the highest raw score (20) converts to a T score of 61.13. A link to the PROMIS scoring maps is provided in the hyperlinks section. An increase in score for cognitive function assessment represents an increase in cognitive function
Time frame: Baseline (start of treatment), day 28 and day 56 (end of treatment)
Change From Baseline in PROMIS® Sleep Disturbance Score at Days 7,14, 21, 28, 35, 42, 49 and End of Treatment (Day 56).
Assessment of change in sleep disturbance between baseline, day 28 and day 56 used the PROMIS® Sleep Disturbance Short Form (see Appendix 5 in Section 17 of the protocol). Four questions are scored between 1 (best score for good quality sleep) and 5 (worst score) such that the lower the score, the better the sleep. Raw scores are converted to a T-score with a mean of 50 and a standard deviation (SD) of 10 for the general population. T-scores of 60 are one SD worse than average (worse quality sleep). By comparison, Sleep Disturbance T-scores of 40 are one SD better than average. The PROMIS Sleep Disturbance scoring manual shows the lowest sleep disturbance score of 4 converting to a T score of 32 with a std error of 5.2, while the highest score of 20 converts to a T score of 73.3 with a std error of 4.6. The change from baseline is based on patients with paired values.
Time frame: Between Baseline (day 0), Visit 4 (day 7), Visit 6 (day 14), Visit 8 (day 21) Visit 10 (day 28), Visit 12 (day 35), Visit 14 (day 42), Visit 16 (Day 56) and Visit 17 (day 56, end of treatment).
Number of Participants Requiring Hospitalization During the Treatment Phase
Number of participants who required hospitalization during the treatment phase.
Time frame: Between baseline (start of treatment) and day 56 (end of treatment)
Duration (Days) of Hospitalization During the Treatment Phase
Duration (in days) of hospitalization required during treatment phase
Time frame: Between baseline (start of treatment) and day 56 (end of treatment)
Change From Baseline in Pulse Oxygen Saturation (SpO2) at Day 7, 14, 21, 28, 35, 42, 49, and 56
Exploratory Outcome - Change from baseline in pulse oxygen saturation (SpO2) at Day 7, 14, 21, 28, 35, 42, 49, and 56
Time frame: Change between baseline (start of treatment) and Day 7, 14, 21, 28, 35, 42, 49, and 56 (end of treatment).
Change From Baseline in Serum Cytokine and Chemokine Levels on Days 28 and 56.
Exploratory Outcome - Change from baseline in serum cytokine and chemokine levels
Time frame: Change between baseline (start of treatment) and days 28 and 56 (end of treatment)
Change From Baseline in CD4+ and CD8+ T Cell Count on Days 28 and 56.
Exploratory Outcome - Change from baseline in CD4+ and CD8+ T cell count
Time frame: Change between baseline (start of treatment) and days 28 and 56 (end of treatment)
Change From Baseline in Transforming Growth Factor Beta 1 (TGF beta1) on Days 28 and 56
Exploratory Outcome - change in TGF-b1 from baseline to days 28 and 56 (end of treatment)
Time frame: Change between baseline (start of treatment) and days 28 and 56 (end of treatment)
Change From Baseline in C-reactive Protein (CRP) on Days 28 and 56
Exploratory Outcome - Change in C-reactive Protein (CRP) from baseline to Days 28 and 56 (end of treatment)
Time frame: Change between baseline (start of treatment) and days 28 and 56 (end of treatment)
Change From Baseline in CCR5 Receptor Occupancy on Days 28 and 56.
Exploratory Outcome - Change in CCR5 receptor occupancy from baseline and days 28 and 56 (end of treatment)
Time frame: Change between baseline (start of treatment) and days 28 and 56 (end of treatment)
Exploration of Biomarkers That May Predict and/or Act as Pharmacodynamic Indicators of Pharmacologic Activity of Leronlimab.
Exploratory Outcome - Exploration of biomarkers that may predict and/or act as pharmacodynamic indicators of pharmacologic activity of leronlimab.
Time frame: 91 Days
Incidence of Treatment-related Adverse Events (TEAEs)
Safety Measurement - incidence of treatment emergent adverse events
Time frame: Between baseline and day 91
Incidence and Severity of Treatment-emergent Adverse Events (TEAEs)
Safety Measures - Incidence and severity of treatment-emergent adverse events
Time frame: Between baseline and day 91
Incidence of Serious Adverse Events (SAEs)
Safety Measures - incidence of severe adverse events
Time frame: Between baseline and day 91
Incidence of TEAEs and SAEs Leading to Discontinuation of Study Medication.
Safety Measures - incidence of TEAEs and SAEs leading to discontinuation of study medication
Time frame: Between baseline and day 56
Changes in Blood Chemistry, Hematology and Coagulation Parameter Results
Safety Measures - Changes in blood chemistry, hematology and coagulation parameter results
Time frame: Between baseline and day 91
Changes in Vital Signs Including Temperature, Pulse, Respiratory Rate, Systolic and Diastolic Blood Pressure
Safety Measures - Changes in vital signs including temperature, pulse, respiratory rate, systolic and diastolic blood pressure
Time frame: Between baseline and day 91
Changes in Physical Examination Results
Safety Measures - Changes in physical examination results
Time frame: Between baseline and day 91
Changes in Electrocardiogram (ECG) Results
Safety Measures - changes in electrocardiogram results
Time frame: Change between baseline and day 91
Fifty six (56) subjects were enrolled in the study with 28 subjects in each treatment arm. All patients were enrolled under protocol version 3.0 (effective date 25-Feb-2021). The study was performed between 01 March 2021 and 01 July 2021.
| Milestone | Placebo | 700mg Leronlimab |
|---|---|---|
| Started | 28 | 28 |
| Completed | 26 | 27 |
| Not completed | 2 | 1 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Changes in common COVID-19-related symptoms were evaluated daily by the patient using a patient diary between start and end of treatment. The diary is shown in Appendix 17.1 in the protocol and covers patient-reported changes for symptoms (ranked as none = 0, mild = 1, moderate = 2 or severe = 3) of cough, sore throat, stuffy or runny nose, difficulty breathing, feeling tightness in chest, feeling fast heartbeat, fatigue, exertional malaise, muscle aches and cramps, muscle weakness, joint pain and swelling, shivering and chills, feeling hot or feverish, difficulty concentrating, insomnia, headache, dizziness, anxiety, tingling or numbness, nausea, vomiting, diarrhea, sense of smell, sense of taste. Maximum score could be 70 (22 parameters with scores up to 3, two parameters with scores up to 2), lowest score could be 0. A negative value shows improvement in symptoms. The lower the value, the greater the improvement (i.e., a score of -16 is greater improvement than a score of -8).
| units on a scale | 700mg Leronlimab | Placebo |
|---|---|---|
| Changes From Baseline in Daily COVID-19-related Symptom Severity Score Through Day 56. | -16.3 ± 13.14 | -8.1 ± 12.27 |
Number of days when any symptoms scored as moderate or severe at baseline (Day 0) are still scored as moderate or severe through day 56 (end of treatment) or symptoms scored as mild or absent at baseline are scored as mild or worse at day 56 (end of treatment).
| days | 700mg Leronlimab | Placebo |
|---|---|---|
| Duration (days) of cough | 14.9 ± 18.8 | 7.8 ± 12.8 |
| Duration (days) of sore throat | 10.6 ± 15.7 | 9.4 ± 13.4 |
| Duration (days) of Stuff/Runny Nose | 19.3 ± 23.0 | 20.7 ± 20.9 |
| Duration (days) of shortness of breath | 11.5 ± 17.4 | 13.9 ± 17.4 |
| Duration (days) of tightness of chest | 10.3 ± 14.8 | 12.3 ± 17.1 |
| Duration (days) of fast heartbeat | 14.8 ± 18.7 | 16.0 ± 15.6 |
| Duration (days) of fatigue | 6.5 ± 14.0 | 10.6 ± 18.4 |
| Duration (days) of exertional malaise | 12.7 ± 18.8 | 10.6 ± 15.3 |
| Duration (days) muscle aches / cramps | 16.5 ± 19.6 | 17.7 ± 16.6 |
| Duration (days) of Muscle Weakness | 17.1 ± 19.4 | 20.8 ± 17.9 |
| Duration (days) joint pain/swelling | 15.9 ± 16.7 | 18.3 ± 18.6 |
| Duration (days) of chills or shivering | 6.6 ± 11.1 | 3.9 ± 7.7 |
| Duration (days) of feeling hot or feverish | 10.5 ± 13.6 | 9.9 ± 16.2 |
| Duration (days) of difficulty in concentration | 15.6 ± 20.3 | 11.8 ± 17.7 |
| Duration (days) of sleep disturbance | 13.3 ± 17.2 | 14.4 ± 17.5 |
| Duration (days) of headache | 16.0 ± 16.6 | 17.8 ± 18.0 |
| Duration (days) of dizziness | 11.8 ± 17.6 | 16.9 ± 18.6 |
| Duration (days) of anxiety | 16.8 ± 22.3 | 15.1 ± 17.4 |
| Duration (days) of tingling or numbness | 14.0 ± 19.3 | 18.3 ± 19.4 |
| Duration (days) of nausea | 6.8 ± 9.8 | 8.5 ± 12.5 |
| Duration (days) of vomiting | 0.3 ± 0.7 | 0.6 ± 1.6 |
| Duration (days) of diarrhea | 8.5 ± 13.7 | 7.1 ± 9.5 |
| Duration (days) of change to sense of smell | 16.8 ± 21.2 | 8.5 ± 15.5 |
| Duration (days) in change of sense of taste | 13.5 ± 18.3 | 8.6 ± 17.0 |
Symptom-free days are defined as number of days when any symptoms scored as mild, moderate or severe at baseline are scored as absent (or none) through Day 56 (end of treatment) using a self-assessment diary.
| Days | 700mg Leronlimab | Placebo |
|---|---|---|
| Days free of cough | 16.8 ± 19.4 | 11.3 ± 17.1 |
| Days free of sore throat | 4.9 ± 9.8 | 11.5 ± 18.5 |
| Days free of stuffy or runny nose | 8.7 ± 13.2 | 12.8 ± 17.7 |
| Days free of shortness of breath | 8.2 ± 12.0 | 15.0 ± 17.0 |
| Days free of tightness of chest | 10.3 ± 16.1 | 13.4 ± 19.0 |
| Days free of fast heartbeat | 12.8 ± 16.5 | 16.4 ± 18.8 |
| Days free of fatigue | 3.9 ± 7.5 | 5.4 ± 10.9 |
| Days free of exertional malaise | 7.2 ± 10.5 | 11.1 ± 15.0 |
| Days free of muscle aches and cramps | 9.1 ± 13.7 | 14.2 ± 15.5 |
| Days free of muscle weakness | 9.5 ± 14.7 | 12.0 ± 16.1 |
| Days free of joint pain/swelling | 10.5 ± 17.8 | 5.1 ± 12.7 |
| Days free of chills or shivering | 12.6 ± 19.4 | 16.6 ± 21.6 |
| Days free of being hot or feverish | 14.8 ± 20.4 | 14.5 ± 18.2 |
| Days free from difficulty concentrating | 4.6 ± 9.1 | 7.4 ± 13.3 |
| Days free from sleep disturbance | 10.3 ± 12.1 | 13.6 ± 15.7 |
| Days free from headache | 15.4 ± 16.2 | 12.5 ± 16.4 |
| Days free from dizziness | 11.0 ± 18.5 | 9.9 ± 15.3 |
| Days free from anxiety | 5.1 ± 11.0 | 12.4 ± 16.4 |
| Days free from tingling or numbness | 16.5 ± 20.1 | 9.0 ± 15.8 |
| Days free from nausea | 14.0 ± 19.8 | 13.9 ± 18.1 |
| Days free from diarrhea | 8.3 ± 15.0 | 13.6 ± 18.3 |
| Days free from change in sense of smell | 7.8 ± 14.2 | 6.9 ± 15.3 |
| Days free from change in sense of taste | 8.8 ± 16.3 | 8.0 ± 16.9 |
Progression or worsening of symptoms is defined as number of days when any symptoms scored as 2 at baseline scored as 3 through day 56 or 1 at baseline are scored as 2 or 3 through day 56 or scored 0 at study entry scored as 1, 2 or 3 through day 56. No change in symptoms would give a score of 0, symptom progression would give a positive number, symptom improvement would a negative number. Minimum baseline symptom score for eligibility for the study was 6. Maximum symptom score is 70, therefore if all symptoms progressed to the severest level the change in score would be +64. If all patients had a severe score for all symptoms at baseline and all improved to no symptoms at day 56, the maximum improvement in score would be -70.
| score on a scale | 700mg Leronlimab | Placebo |
|---|---|---|
| Cough | -0.6 ± 0.8 | -0.4 ± 0.9 |
| Sore throat | -0.1 ± 0.7 | -0.2 ± 0.8 |
| Stuffy or runny nose | -0.7 ± 0.8 | -0.1 ± 0.8 |
| Shortness of breath | -0.8 ± 1.0 | -0.6 ± 0.9 |
| Tightness of chest | -0.6 ± 0.9 | -0.3 ± 0.9 |
| Fast heartbeat | -0.8 ± 0.8 | -0.5 ± 1.0 |
| Fatigue | -1.1 ± 0.9 | -1.1 ± 1.0 |
| Exertional Malaise | -1.1 ± 1.1 | -0.9 ± 1.0 |
| Muscle aches and cramps | -0.9 ± 0.9 | -0.7 ± 0.9 |
| Muscle weakness | -0.9 ± 1.1 | -0.5 ± 0.8 |
| Joint Pain/swelling | -0.8 ± 0.7 | -0.3 ± 0.9 |
| Chills and shivering | -0.6 ± 0.6 | -0.5 ± 0.8 |
| Hot or feverish | -0.5 ± 0.8 | -0.6 ± 1.1 |
| Difficulty in concentrating | -1.0 ± 1.0 | -1.1 ± 1.0 |
| Sleep disturbance | -1.2 ± 0.9 | -1.1 ± 1.0 |
| Headache | -1.0 ± 1.0 | -0.7 ± 1.0 |
| Dizziness | -0.7 ± 1.0 | -0.4 ± 0.9 |
| Anxiety | -0.7 ± 0.9 | -0.8 ± 0.8 |
| Tingling or numbness | -0.8 ± 1.0 | -0.3 ± 0.9 |
| Nausea | -0.6 ± 0.9 | -0.5 ± 0.9 |
| Vomiting | 0.0 ± 0.1 | 0.0 ± 0.1 |
| Diarrhea | -0.0 ± 0.6 | -0.6 ± 1.0 |
| Sense of Smell | -0.3 ± 0.5 | -0.2 ± 0.4 |
| Sense of taste | -0.3 ± 0.5 | -0.2 ± 0.4 |
Change from baseline in physical and psychological fatigue measured using the PROMIS® scale. A decrease in the score compared to baseline shows an improvement in the symptom. PROMIS definition - Patient-Reported Outcomes Measurement Information System. The Fatigue Short Form (4a) was used (Section 17.3 Appendix 3 of protocol). Raw fatigue scores range from 4 to 20 and are converted to a T-score metric where the response from the general population is set at 50 with standard deviations at 10; a score of greater than 60 would be one std dev greater than the general population, meaning more fatigue. A link to the fatigue score maps is provided in the hyperlinks section. The minimum fatigue T-score is 33.7 (with a std error of 4.9) and a maximum score of 75.8 (with a std error of 3.9). The higher the score, the more fatigue. A decrease in the fatigue score from baseline to day 28 and day 56 would indicate decrease in fatigue.
| Units on a scale | 700mg Leronlimab | Placebo |
|---|---|---|
| Baseline score (day 0) | 68.4 ± 6.5 | 66.6 ± 7.1 |
| Change from baseline to visit 4 (day 7) | -5.3 ± 9.9 | -6.1 ± 8.5 |
| Change from baseline to visit 6 (day 14) | -7.6 ± 10.7 | -7.6 ± 8.5 |
| Change from baseline to visit 8 (day 21) | -8.4 ± 14.6 | -10.2 ± 10.1 |
| Change from baseline to visit 10 (day 28) | -8.8 ± 12.1 | -7.5 ± 10.5 |
| Change from baseline to Visit 12 (day 25) | -11.1 ± 13.4 | -8.6 ± 10.8 |
| Change from baseline to visit 14 (day 42) | -11.0 ± 14.0 | -8.1 ± 11.2 |
| change from baseline to visit 16 (day 49) | -11.8 ± 12.9 | -11.0 ± 11.5 |
| Change from baseline to end of treatment (day 56) | -11.1 ± 11.9 | -10.2 ± 10.8 |
Change in cognitive function score between baseline, day 28 and day 56 were measured using the PROMIS Cognitive Function Assessment Short Form 4a. Higher scores on the PROMIS Cognitive Function Assessment indicate better perceived cognitive functioning. Answers to 4 questions with scores ranging from 1 (very often - several times a day) to 5 (never) provide raw scores that are then normalized T scores. A T score of 50 is the mean of the general population, with std devs of 10, therefore a score of 40 is one std dev lower than that of the general population. The lowest raw score (4) converts to a T score of 24.99 while the highest raw score (20) converts to a T score of 61.13. A link to the PROMIS scoring maps is provided in the hyperlinks section. An increase in score for cognitive function assessment represents an increase in cognitive function
| units on a scale | 700mg Leronlimab | Placebo |
|---|---|---|
| Baseline (day 0) | 29.6 ± 5.5 | 34.6 ± 9.5 |
| Change from baseline to visit 4 (day 7) | 5.1 ± 8.9 | 2.7 ± 8.2 |
| Change from baseline to visit 6 (day 14) | 7.4 ± 9.6 | 4.9 ± 9.5 |
| Change from baseline to visit 8 (day 21) | 7.4 ± 10.0 | 4.6 ± 7.9 |
| Change from baseline to visit 10 (day 28) | 9.0 ± 8.9 | 4.1 ± 8.0 |
| Change from baseline to visit 12 (day 35) | 10.1 ± 9.4 | 6.2 ± 9.1 |
| Change from baseline to visit 14 (day 42) | 10.8 ± 11.2 | 6.2 ± 8.6 |
| Change from baseline to visit 16 (day 49) | 10.3 ± 10.8 | 7.4 ± 9.7 |
| Change from baseline to end of treatment (day 56) | 10.9 ± 10.8 | 6.3 ± 8.8 |
Assessment of change in sleep disturbance between baseline, day 28 and day 56 used the PROMIS® Sleep Disturbance Short Form (see Appendix 5 in Section 17 of the protocol). Four questions are scored between 1 (best score for good quality sleep) and 5 (worst score) such that the lower the score, the better the sleep. Raw scores are converted to a T-score with a mean of 50 and a standard deviation (SD) of 10 for the general population. T-scores of 60 are one SD worse than average (worse quality sleep). By comparison, Sleep Disturbance T-scores of 40 are one SD better than average. The PROMIS Sleep Disturbance scoring manual shows the lowest sleep disturbance score of 4 converting to a T score of 32 with a std error of 5.2, while the highest score of 20 converts to a T score of 73.3 with a std error of 4.6. The change from baseline is based on patients with paired values.
| score on a scale | 700mg Leronlimab | Placebo |
|---|---|---|
| Baseline score (day 0) | 60.2 ± 8.0 | 58.3 ± 8.5 |
| Change from baseline to visit 4 (day 7) | -4.1 ± 8.6 | -1.9 ± 6.2 |
| Change from baseline to visit 6 (day 14) | -5.3 ± 9.6 | -3.4 ± 8.0 |
| Change from baseline visit 8 (day 21) | -7.7 ± 10.2 | -5.1 ± 7.1 |
| Change from baseline to visit 10 (day 28) | -7.2 ± 8.9 | -5.7 ± 9.2 |
| Change from baseline to visit 12 (day 35) | -8.3 ± 10.8 | -4.2 ± 6.5 |
| Change from baseline to visit 14 (day 42) | -7.7 ± 10.7 | -5.3 ± 7.9 |
| Change from baseline to visit 16 (day 49) | -7.6 ± 9.5 | -6.0 ± 10.4 |
| Change from baseline to end of treatment (day 56) | -8.3 ± 9.4 | -5.5 ± 9.4 |
Number of participants who required hospitalization during the treatment phase.
| Participants | 700mg Leronlimab | Placebo |
|---|---|---|
| Number of Participants Requiring Hospitalization During the Treatment Phase | 0 | 0 |
Duration (in days) of hospitalization required during treatment phase
| days | 700mg Leronlimab | Placebo |
|---|---|---|
| Duration (Days) of Hospitalization During the Treatment Phase | 0 | 0 |
Exploratory Outcome - Change from baseline in pulse oxygen saturation (SpO2) at Day 7, 14, 21, 28, 35, 42, 49, and 56
Results for this outcome have not been posted.
Exploratory Outcome - Change from baseline in serum cytokine and chemokine levels
Results for this outcome have not been posted.
Exploratory Outcome - Change from baseline in CD4+ and CD8+ T cell count
Results for this outcome have not been posted.
Exploratory Outcome - change in TGF-b1 from baseline to days 28 and 56 (end of treatment)
Results for this outcome have not been posted.
Exploratory Outcome - Change in C-reactive Protein (CRP) from baseline to Days 28 and 56 (end of treatment)
Results for this outcome have not been posted.
Exploratory Outcome - Change in CCR5 receptor occupancy from baseline and days 28 and 56 (end of treatment)
Results for this outcome have not been posted.
Exploratory Outcome - Exploration of biomarkers that may predict and/or act as pharmacodynamic indicators of pharmacologic activity of leronlimab.
Results for this outcome have not been posted.
Safety Measurement - incidence of treatment emergent adverse events
Results for this outcome have not been posted.
Safety Measures - Incidence and severity of treatment-emergent adverse events
Results for this outcome have not been posted.
Safety Measures - incidence of severe adverse events
Results for this outcome have not been posted.
Safety Measures - incidence of TEAEs and SAEs leading to discontinuation of study medication
Results for this outcome have not been posted.
Safety Measures - Changes in blood chemistry, hematology and coagulation parameter results
Results for this outcome have not been posted.
Safety Measures - Changes in vital signs including temperature, pulse, respiratory rate, systolic and diastolic blood pressure
Results for this outcome have not been posted.
Safety Measures - Changes in physical examination results
Results for this outcome have not been posted.
Safety Measures - changes in electrocardiogram results
Results for this outcome have not been posted.
Collected over Adverse event data was collected between start of treatment (baseline, day 0) and 28 days after end of treatment. First dose was administered on Day 0, last dose (dose 8) was administered on day 49, End of Treatment (EOT) was 7 days after last dose (day 56) and follow-up was for the 28 day period after the EOT visit.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 700mg Leronlimab | 0/28 (0%) | 0/28 (0%) | 22/28 (78.6%) |
| Placebo | 0/28 (0%) | 1/28 (3.6%) | 20/28 (71.4%) |
| Event | 700mg Leronlimab | Placebo |
|---|---|---|
| Seizures and seizure disordersNervous system disorders | 0/28 | 1/28 |
| Event | 700mg Leronlimab | Placebo |
|---|---|---|
| Urinary tract infectionInfections and infestations | 2/28 | 4/28 |
| HypokalaemiaMetabolism and nutrition disorders | 0/28 | 3/28 |
| AnxietyPsychiatric disorders | 3/28 | 0/28 |
| RashSkin and subcutaneous tissue disorders | 1/28 | 3/28 |
| DiarrhoeaGastrointestinal disorders | 0/28 | 2/28 |
| NauseaGastrointestinal disorders | 1/28 | 2/28 |
| VomitingGastrointestinal disorders | 2/28 | 0/28 |
| Chest PainGeneral disorders | 2/28 | 0/28 |
| Injection site reactionGeneral disorders | 2/28 | 0/28 |
| MalaiseGeneral disorders | 2/28 | 0/28 |
The Modified Intent-to-Treat (mITT) population is defined as the set of subjects who have received at least one dose of study treatment (leronlimab or placebo). This population was used for the analysis of efficacy parameters or measurements. The Safety Population includes all subjects who received one dose of study treatment (leronlimab or placebo). This population was used for the analysis of safety parameters or measurements.
| Age, Categorical(Participants) | 700mg Leronlimab | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 26 | 23 | 49 |
| >=65 years | 2 | 5 | 7 |
| Age, Continuous(years) | 700mg Leronlimab | Placebo | Total |
|---|---|---|---|
| Mean | 45.5 ± 12.8 | 51.6 ± 13.2 | 48.6 ± 13.24 |
| Sex: Female, Male(Participants) | 700mg Leronlimab | Placebo | Total |
|---|---|---|---|
| Female | 18 | 18 | 36 |
| Male | 10 | 10 | 20 |
| Ethnicity (NIH/OMB)(Participants) | 700mg Leronlimab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 25 | 27 | 52 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 700mg Leronlimab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 28 | 27 | 55 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | 700mg Leronlimab | Placebo | Total |
|---|---|---|---|
| United States | 28 | 28 | 56 |
| Baseline COVID-19 Related Symptom Score(units on a scale) | 700mg Leronlimab | Placebo | Total |
|---|---|---|---|
| Mean | 32.5 ± 9.96 | 26.9 ± 10.19 | 29.4 ± 10.64 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Jun 2021, 3 months.
Results were first posted in Apr 2024, 2 years 10 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 3 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leronlimab